Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02771574 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Tolerability and Pharmacokinetics of Subcutaneous Exendin (9-39) in Patients With Post Bariatric Hypoglycemia
A Phase 2 study, sponsored by Tracey McLaughlin.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT02771574: Completed Phase 2 study, sponsored by Tracey McLaughlin.
NCT02771574 is a Phase 2 study that has completed, run by Tracey McLaughlin. The registered enrollment target is 19 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02771574, a Phase 2 study, has completed, sponsored by Tracey McLaughlin.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
This study is designed to evaluate the efficacy, safety and pharmacokinetics of subcutaneous exendin (9-39) in subjects with post-bariatric hypoglycemia. Development of this subcutaneous formulation of exendin (9-39) would represent a targeted therapeutic approach for this rare disease with unmet clinical need.
Primary Outcome
Nadir glucose at baseline and at Day 3 of treatment during oral glucose tolerance test (OGTT).
Interventions
- DRUG Lyo avexitide
- DRUG Liq avexitide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2016-05 |
| Est. Completion | 2017-06 |
| Phase | Phase 2 |
What the finished NCT02771574 record still lists
NCT02771574 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower).
The record links to 0 conditions, and to 2 interventions - of which Lyo avexitide is the first listed.
NCT02771574 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02771574 about?
NCT02771574 is a clinical study titled "Efficacy, Tolerability and Pharmacokinetics of Subcutaneous Exendin (9-39) in Patients With Post Bariatric Hypoglycemia". This study is designed to evaluate the efficacy, safety and pharmacokinetics of subcutaneous exendin (9-39) in subjects with post-bariatric hypoglycemia. Development of this subcutaneous formulation of exendin (9-39) would represent a targeted therapeutic approach for this rare disease with unmet cl...
What is the current status of trial NCT02771574?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2016-05. Estimated completion is 2017-06.
What interventions are being tested in trial NCT02771574?
The interventions under investigation include: Lyo avexitide (DRUG), Liq avexitide (DRUG).
Who is sponsoring clinical trial NCT02771574?
This trial is sponsored by Tracey McLaughlin, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02771574's enrollment target sits among peer trials
19 1894th of 2000 higher than 103 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia